Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

SELL
$1.17 - $2.61 $12,051 - $26,883
-10,300 Reduced 88.79%
1,300 $2,000
Q1 2022

May 16, 2022

BUY
$2.11 - $7.25 $24,476 - $84,100
11,600 New
11,600 $28,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $184M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.